Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma

Anna Planagumà, Shamsah Kazani, Gautham Marigowda, Oliver Haworth, Thomas J. Mariani, Elliot Israel, Eugene R. Bleecker, Douglas Curran-Everett, Serpil C. Erzurum, William Calhoun, Mario Castro, Fan Chung Kian, Benjamin Gaston, Nizar N. Jarjour, William W. Busse, Sally E. Wenzel, Bruce D. Levy

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Rationale: Airway inflammation is common in severe asthma despite antiinflammatory therapy with corticosteroids. Lipoxin A4 (LXA 4) is an arachidonic acid-derived mediator that serves as an agonist for resolution of inflammation. Objectives: Airway levels of LXA4, as well as the expression of lipoxin biosynthetic genes and receptors, in severe asthma. Methods: Samples of bronchoalveolar lavage fluid were obtained from subjects with asthma and levels of LXA4 and related eicosanoids were measured. Expression of lipoxin biosynthetic genes was determined in whole blood, bronchoalveolar lavage cells, and endobronchial biopsies by quantitative polymerase chain reaction, and leukocyte LXA4 receptors were monitored by flow cytometry. Measurements and Main Results: Individuals with severe asthma had significantly less LXA4 in bronchoalveolar lavage fluids (11.2 ± 2.1 pg/ml) than did subjects with nonsevere asthma (150.1 ± 38.5 pg/ml; P < 0.05). In contrast, levels of cysteinyl leukotrienes were increased in both asthma cohorts compared with healthy individuals. In severe asthma, 15-lipoxygenase-1 mean expression was decreased fivefold in bronchoalveolar lavage cells. In contrast, 15-lipoxgenase-1 was increased threefold in endobronchial biopsies, but expression of both 5-lipoxygenase and 15-lipoxygenase-2 in these samples was decreased. Cyclooxygenase-2 expression was decreased in all anatomic compartments sampled in severe asthma. Moreover, LXA4 receptor gene and protein expression were significantly decreased in severe asthma peripheral blood granulocytes. Conclusions: Mechanisms underlying pathological airway responses in severe asthma include lipoxin underproduction with decreased expression of lipoxin biosynthetic enzymesand receptors. Together, these results indicate that severe asthma is characterized, in part, by defective lipoxin counterregulatory signaling circuits.

Original languageEnglish (US)
Pages (from-to)574-582
Number of pages9
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume178
Issue number6
DOIs
StatePublished - Sep 15 2008

Fingerprint

Lipoxin Receptors
Asthma
Lipoxins
Arachidonate 15-Lipoxygenase
Lipoxygenase
Bronchoalveolar Lavage Fluid
Bronchoalveolar Lavage
lipoxin A4
Inflammation
Biopsy
Arachidonate 5-Lipoxygenase
Eicosanoids
Cyclooxygenase 2

Keywords

  • Eicosanoids
  • Lipoxins
  • Severe asthma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Planagumà, A., Kazani, S., Marigowda, G., Haworth, O., Mariani, T. J., Israel, E., ... Levy, B. D. (2008). Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. American Journal of Respiratory and Critical Care Medicine, 178(6), 574-582. https://doi.org/10.1164/rccm.200801-061OC

Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. / Planagumà, Anna; Kazani, Shamsah; Marigowda, Gautham; Haworth, Oliver; Mariani, Thomas J.; Israel, Elliot; Bleecker, Eugene R.; Curran-Everett, Douglas; Erzurum, Serpil C.; Calhoun, William; Castro, Mario; Kian, Fan Chung; Gaston, Benjamin; Jarjour, Nizar N.; Busse, William W.; Wenzel, Sally E.; Levy, Bruce D.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 178, No. 6, 15.09.2008, p. 574-582.

Research output: Contribution to journalArticle

Planagumà, A, Kazani, S, Marigowda, G, Haworth, O, Mariani, TJ, Israel, E, Bleecker, ER, Curran-Everett, D, Erzurum, SC, Calhoun, W, Castro, M, Kian, FC, Gaston, B, Jarjour, NN, Busse, WW, Wenzel, SE & Levy, BD 2008, 'Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma', American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 6, pp. 574-582. https://doi.org/10.1164/rccm.200801-061OC
Planagumà, Anna ; Kazani, Shamsah ; Marigowda, Gautham ; Haworth, Oliver ; Mariani, Thomas J. ; Israel, Elliot ; Bleecker, Eugene R. ; Curran-Everett, Douglas ; Erzurum, Serpil C. ; Calhoun, William ; Castro, Mario ; Kian, Fan Chung ; Gaston, Benjamin ; Jarjour, Nizar N. ; Busse, William W. ; Wenzel, Sally E. ; Levy, Bruce D. / Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. In: American Journal of Respiratory and Critical Care Medicine. 2008 ; Vol. 178, No. 6. pp. 574-582.
@article{eeecee5d2ab641b7adbdf98951e2368f,
title = "Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma",
abstract = "Rationale: Airway inflammation is common in severe asthma despite antiinflammatory therapy with corticosteroids. Lipoxin A4 (LXA 4) is an arachidonic acid-derived mediator that serves as an agonist for resolution of inflammation. Objectives: Airway levels of LXA4, as well as the expression of lipoxin biosynthetic genes and receptors, in severe asthma. Methods: Samples of bronchoalveolar lavage fluid were obtained from subjects with asthma and levels of LXA4 and related eicosanoids were measured. Expression of lipoxin biosynthetic genes was determined in whole blood, bronchoalveolar lavage cells, and endobronchial biopsies by quantitative polymerase chain reaction, and leukocyte LXA4 receptors were monitored by flow cytometry. Measurements and Main Results: Individuals with severe asthma had significantly less LXA4 in bronchoalveolar lavage fluids (11.2 ± 2.1 pg/ml) than did subjects with nonsevere asthma (150.1 ± 38.5 pg/ml; P < 0.05). In contrast, levels of cysteinyl leukotrienes were increased in both asthma cohorts compared with healthy individuals. In severe asthma, 15-lipoxygenase-1 mean expression was decreased fivefold in bronchoalveolar lavage cells. In contrast, 15-lipoxgenase-1 was increased threefold in endobronchial biopsies, but expression of both 5-lipoxygenase and 15-lipoxygenase-2 in these samples was decreased. Cyclooxygenase-2 expression was decreased in all anatomic compartments sampled in severe asthma. Moreover, LXA4 receptor gene and protein expression were significantly decreased in severe asthma peripheral blood granulocytes. Conclusions: Mechanisms underlying pathological airway responses in severe asthma include lipoxin underproduction with decreased expression of lipoxin biosynthetic enzymesand receptors. Together, these results indicate that severe asthma is characterized, in part, by defective lipoxin counterregulatory signaling circuits.",
keywords = "Eicosanoids, Lipoxins, Severe asthma",
author = "Anna Planagum{\`a} and Shamsah Kazani and Gautham Marigowda and Oliver Haworth and Mariani, {Thomas J.} and Elliot Israel and Bleecker, {Eugene R.} and Douglas Curran-Everett and Erzurum, {Serpil C.} and William Calhoun and Mario Castro and Kian, {Fan Chung} and Benjamin Gaston and Jarjour, {Nizar N.} and Busse, {William W.} and Wenzel, {Sally E.} and Levy, {Bruce D.}",
year = "2008",
month = "9",
day = "15",
doi = "10.1164/rccm.200801-061OC",
language = "English (US)",
volume = "178",
pages = "574--582",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma

AU - Planagumà, Anna

AU - Kazani, Shamsah

AU - Marigowda, Gautham

AU - Haworth, Oliver

AU - Mariani, Thomas J.

AU - Israel, Elliot

AU - Bleecker, Eugene R.

AU - Curran-Everett, Douglas

AU - Erzurum, Serpil C.

AU - Calhoun, William

AU - Castro, Mario

AU - Kian, Fan Chung

AU - Gaston, Benjamin

AU - Jarjour, Nizar N.

AU - Busse, William W.

AU - Wenzel, Sally E.

AU - Levy, Bruce D.

PY - 2008/9/15

Y1 - 2008/9/15

N2 - Rationale: Airway inflammation is common in severe asthma despite antiinflammatory therapy with corticosteroids. Lipoxin A4 (LXA 4) is an arachidonic acid-derived mediator that serves as an agonist for resolution of inflammation. Objectives: Airway levels of LXA4, as well as the expression of lipoxin biosynthetic genes and receptors, in severe asthma. Methods: Samples of bronchoalveolar lavage fluid were obtained from subjects with asthma and levels of LXA4 and related eicosanoids were measured. Expression of lipoxin biosynthetic genes was determined in whole blood, bronchoalveolar lavage cells, and endobronchial biopsies by quantitative polymerase chain reaction, and leukocyte LXA4 receptors were monitored by flow cytometry. Measurements and Main Results: Individuals with severe asthma had significantly less LXA4 in bronchoalveolar lavage fluids (11.2 ± 2.1 pg/ml) than did subjects with nonsevere asthma (150.1 ± 38.5 pg/ml; P < 0.05). In contrast, levels of cysteinyl leukotrienes were increased in both asthma cohorts compared with healthy individuals. In severe asthma, 15-lipoxygenase-1 mean expression was decreased fivefold in bronchoalveolar lavage cells. In contrast, 15-lipoxgenase-1 was increased threefold in endobronchial biopsies, but expression of both 5-lipoxygenase and 15-lipoxygenase-2 in these samples was decreased. Cyclooxygenase-2 expression was decreased in all anatomic compartments sampled in severe asthma. Moreover, LXA4 receptor gene and protein expression were significantly decreased in severe asthma peripheral blood granulocytes. Conclusions: Mechanisms underlying pathological airway responses in severe asthma include lipoxin underproduction with decreased expression of lipoxin biosynthetic enzymesand receptors. Together, these results indicate that severe asthma is characterized, in part, by defective lipoxin counterregulatory signaling circuits.

AB - Rationale: Airway inflammation is common in severe asthma despite antiinflammatory therapy with corticosteroids. Lipoxin A4 (LXA 4) is an arachidonic acid-derived mediator that serves as an agonist for resolution of inflammation. Objectives: Airway levels of LXA4, as well as the expression of lipoxin biosynthetic genes and receptors, in severe asthma. Methods: Samples of bronchoalveolar lavage fluid were obtained from subjects with asthma and levels of LXA4 and related eicosanoids were measured. Expression of lipoxin biosynthetic genes was determined in whole blood, bronchoalveolar lavage cells, and endobronchial biopsies by quantitative polymerase chain reaction, and leukocyte LXA4 receptors were monitored by flow cytometry. Measurements and Main Results: Individuals with severe asthma had significantly less LXA4 in bronchoalveolar lavage fluids (11.2 ± 2.1 pg/ml) than did subjects with nonsevere asthma (150.1 ± 38.5 pg/ml; P < 0.05). In contrast, levels of cysteinyl leukotrienes were increased in both asthma cohorts compared with healthy individuals. In severe asthma, 15-lipoxygenase-1 mean expression was decreased fivefold in bronchoalveolar lavage cells. In contrast, 15-lipoxgenase-1 was increased threefold in endobronchial biopsies, but expression of both 5-lipoxygenase and 15-lipoxygenase-2 in these samples was decreased. Cyclooxygenase-2 expression was decreased in all anatomic compartments sampled in severe asthma. Moreover, LXA4 receptor gene and protein expression were significantly decreased in severe asthma peripheral blood granulocytes. Conclusions: Mechanisms underlying pathological airway responses in severe asthma include lipoxin underproduction with decreased expression of lipoxin biosynthetic enzymesand receptors. Together, these results indicate that severe asthma is characterized, in part, by defective lipoxin counterregulatory signaling circuits.

KW - Eicosanoids

KW - Lipoxins

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=51849153327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51849153327&partnerID=8YFLogxK

U2 - 10.1164/rccm.200801-061OC

DO - 10.1164/rccm.200801-061OC

M3 - Article

VL - 178

SP - 574

EP - 582

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -